DOCSLIB.ORG

Synthesis and Discovery of the Putative Cognitive Enhancer BRS- 015: Effect on Glutamatergic Transmission and Synaptic Plasticity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Synthesis and Discovery of the Putative Cognitive Enhancer BRS- 015: Effect on Glutamatergic Transmission and Synaptic Plasticity UCL SCHOOL OF PHARMACY BRUNSWICK SQUARE Synthesis and discovery of the putative cognitive enhancer BRS- 015: effect on glutamatergic transmission and synaptic plasticity Blanka Szulc Supervisors: Dr Stephen Hilton and Dr Arnaud Ruiz 29/07/2014 This research project is submitted in part fulfilment of the requirements for the PhD degree, UCL School of Pharmacy Department of Pharmaceutical and Biological Chemistry and the Pharmacology Department Blanka Szulc Discovery and mode of action of BRS-015 Abstract This thesis is concerned with the discovery of a novel heterocyclic compound – BRS-015, its synthesis and an analysis of its effects on excitatory synaptic transmission at a major pathway in the brain. BRS-015 is related to the natural product clausenamide, which has been shown to facilitate synaptic transmission. As such, clausenamide and related analogues may possess therapeutic potential as memory enhancing drugs, which are in urgent need of development due to the increasing numbers of patients diagnosed with memory disorders and for which there is no current effective therapy. BRS-015 was synthesized using a novel approach to the core structure of clausenamide involving an intramolecular acylal cyclisation reaction, which has not previously been reported. The first section of the thesis opens with a description of the discovery, structure and biological activity of clausenamide and discussion of previous synthetic strategies adopted by a number of research groups and attempts to classify these into the varying approaches towards the central core of clausenamide. The second section describes the structure of the rat brain and the types of processes involved in memory formation, as well as the neurophysiological assays used to investigate synaptic transmission and plasticity. The second group of chapters describes our own approach to the core of clausenamide and the synthesis of BRS-015, with a detailed discussion of the structural analysis and investigation of the intramolecular acylal cyclisation reaction used during the synthetic process. The third chapter describes the neurophysiological assays used in our investigations into the effects of BRS-015, which was tested against glutamatergic synaptic transmission and plasticity in acute rat hippocampal slices. BRS-015 was shown to reversibly enhance the amplitude of AMPA receptor mediated EPSCs recorded from CA3 pyramidal neurones and evoked by dentate stimulation. When tested in the presence of selective glutamate receptor antagonists, BRS-015 did not have this powerful enhancing effect on kainate or NMDA receptor mediated EPSCs. In addition, BRS-015 increased the amplitude of glutamate-evoked currents in CA3 pyramidal neurones and did not alter short-term synaptic plasticity but facilitated the induction of mossy fibre LTP, with little effect at associational/commissural synapses. BRS-015 has striking enhancing properties on AMPA receptor mediated synaptic transmission at mossy fibre synapses either by directly interacting with AMPA receptors or via indirect modulation, the mechanisms of which could lead to synapse strengthening. i Blanka Szulc Discovery and mode of action of BRS-015 Acknowledgements Firstly I would like to express my sincere thanks to both of my supervisors - Dr Stephen Hilton and Dr Arnaud Ruiz for all of their help, support and advice during my PhD from transitioning through to electrophysiology from chemistry. Your experience and great guidance enabled me achieve success on such a wide-ranging project. Thank you for all your time and in particular your proof- reading of this thesis! I would secondly like to thank all of my laboratory colleagues in Steve and Arnaud’s labs for all their help and support over the years. Special thanks go to Bruno, Georgina, Bhaven, Moussa, Chris, Zenobia, Raiza, Anna and Antonia for all your help, friendship and advice over my time at UCL School of Pharmacy. I would also like to thank the staff in both departments for their friendship and support who are too numerous to mention. I would like to thank Dr Gary Parkinson for the X-ray structure of the cyclised product and for patiently allowing me to watch him at work. Thank you also to Colin and Mire for your help with NMR and to Emmanual for mass spectrometry. Thanks also go to the team in the biological service unit at the School for their help and advice. I would also like to thank the Leverhulme Trust for generously funding this research, with the provision of a PhD studentship. Lastly, thanks to all of my family and friends, who are close to my heart who have always been there for me. ii Blanka Szulc Discovery and mode of action of BRS-015 Plagiarism Statement I, Blanka Szulc, hereby confirm that the work submitted in the thesis is my own. Any ideas submitted in this thesis are my own. Any ideas, quotations, and paraphrasing from other peoples work and publications have been appropriately referenced. I have not violated UCL School of Pharmacy’s policy on plagiarism. Signature ....................................... Date ............................... iii Blanka Szulc Discovery and mode of action of BRS-015 Abbreviations ABSA p-Acetamidobenzenesulfonyl azide ACSF Artificial cerebrospinal fluid A/C Associational-commisural fibres AD Alzheimer’s disease ADA 5’-Nucleotidase adenosine deaminase ADHD Attention deficit hyperactivity disorder ADME Absorption, distribution, metabolism, elimination AGP α1-Acid glycoprotein AMPA α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid app Apparent BOC tert-Butoxycarbonyl br Broad Bu Butyl °C Degree Celcius CAMKIIα Calcium/calmodulin-dependent protein kinase IIα Cat Catalytic CNS Central nervous system CREB cAMP response element-binding protein d Doublet DABCO Diazabicyclo[2.2.2]octane DBU Diazabicyclo[5.4.0]undec-7-ene DCG-IV (2S,2'R,3'R)–2–(2',3'–Dicarboxycyclopropyl)glycine DCM Dichloromethane DMAP 4-N,N-Dimethylaminopyridine DMF N,N-Dimethylformamide DMSO Dimethylsulfoxide EDTA Ethylenediaminetetraacetic acid ee Enantiomeric excess EPSCs Excitatory postsynaptic currents iv Blanka Szulc Discovery and mode of action of BRS-015 EPSPs Excitatory postsynaptic potentials Et Ethyl EtOAc Ethyl acetate f-EPSPs Field excitatory postsynaptic potentials g Grammes GC Granule cells GCL Granule cell layer h Hours HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid HFS High frequency stimulation HPLC High performance liquid chromatography IAC Intramolecular acylal cyclisation IL-1β Interleukin 1 beta IR Infra red KAR Kainate receptor LDA Lithium diisopropylamide LTD Long-term depression LTP Long term potentiation M Molar m Multiplet mCPBA meta-Chloroperoxybenzoic acid Mes Mesityl Me Methyl MF-LTP Mossy fibre LTP mg Milligrams mGluRs Metabotropic glutamate receptors MFBs Mossy fibre boutons MHz Mega Hertz mL Millilitre ML Molecular layer mmol Millimoles v Blanka Szulc Discovery and mode of action of BRS-015 mp Melting point MS Multiple sclerosis m/z Mass to charge ratio NADPH Nicotinamide adenine dinucleotide phosphate NBS N-Bromosuccinimide NCS N-Chlorosuccinimide NHC N-Heterocyclic carbene NMDA N-Methyl-D-aspartate NMR Nuclear magnetic resonance nOe Nuclear Overhauser effect PG Protecting group PhTx Polyamine toxins PIFA [Bis(trifluoroacetoxy)iodo]benzene PPF Paired pulse facilitation ppm Parts per million PS Population spike PTP Post-tetanic potentiation q Quartet quin Quintet Rf Retention factor ROS Reactive oxygen species rt Room temperature s Secondary s Singlet SAR Structure activity relationship SG Stratum granulosum t Tertiary t Triplet TBDMSCl tert-Butyldimethylsilyl chloride TFA Trifluoroacetic acid THF Tetrahydrofuran vi Blanka Szulc Discovery and mode of action of BRS-015 TLC Thin layer chromatography TMS Tetramethylsilane TMSCl Trimethylsilyl chloride TMSOTf Trimethylsilyl trifluoromethanesulfonate TNF-α Tumor necrosis factor UV Ultra violet μL Microlitre VDCC Voltage-dependent calcium channels vii Blanka Szulc Discovery and mode of action of BRS-015 Contents 1.0. Introduction ................................................................................................ 1 1.1. General Introduction ............................................................................... 2 1.1.1. Memory Deficit Disorders ........................................................................... 2 1.1.2. Nootropic drugs ......................................................................................... 3 1.1.3. AMPA modulators in a clinical setting .......................................................... 9 1.2. Clausenamide ................................................................................................. 11 1.2.1. Mode of action of clausenamide................................................................. 12 1.2.2. Previous synthetic approaches to clausenamide ........................................ 14 1.3. Biological introduction .................................................................................. 24 1.4. Glutamatergic neurotransmission ................................................................ 24 1.5. Ionotropic Glutamate Receptors ................................................................... 25 1.5.1. AMPA receptors ......................................................................................... 26 1.5.2. NMDA receptors ........................................................................................ 27 1.5.3. Kainate receptors ....................................................................................... 28 1.6. Anatomy of the hippocampus ......................................................................
Load more

Recommended publications
  • Mechanisms of Action of Antiepileptic Drugs
    Review Mechanisms of action of antiepileptic drugs Epilepsy affects up to 1% of the general population and causes substantial disability. The management of seizures in patients with epilepsy relies heavily on antiepileptic drugs (AEDs). Phenobarbital, phenytoin, carbamazepine and valproic acid have been the primary medications used to treat epilepsy for several decades. Since 1993 several AEDs have been approved by the US FDA for use in epilepsy. The choice of the AED is based primarily on the seizure type, spectrum of clinical activity, side effect profile and patient characteristics such as age, comorbidities and concurrent medical treatments. Those AEDs with broad- spectrum activity are often found to exert an action at more than one molecular target. This article will review the proposed mechanisms of action of marketed AEDs in the US and discuss the future of AEDs in development. 1 KEYWORDS: AEDs anticonvulsant drugs antiepileptic drugs epilepsy Aaron M Cook mechanism of action seizures & Meriem K Bensalem-Owen† The therapeutic armamentarium for the treat- patients with refractory seizures. The aim of this 1UK HealthCare, 800 Rose St. H-109, ment of seizures has broadened significantly article is to discuss the past, present and future of Lexington, KY 40536-0293, USA †Author for correspondence: over the past decade [1]. Many of the newer AED pharmacology and mechanisms of action. College of Medicine, Department of anti epileptic drugs (AEDs) have clinical advan- Neurology, University of Kentucky, 800 Rose Street, Room L-455, tages over older, so-called ‘first-generation’ First-generation AEDs Lexington, KY 40536, USA AEDs in that they are more predictable in their Broadly, the mechanisms of action of AEDs can Tel.: +1 859 323 0229 Fax: +1 859 323 5943 dose–response profile and typically are associ- be categorized by their effects on the neuronal [email protected] ated with less drug–drug interactions.
    [Show full text]
  • PR2 2009.Vp:Corelventura
    Pharmacological Reports Copyright © 2009 2009, 61, 197216 by Institute of Pharmacology ISSN 1734-1140 Polish Academy of Sciences Review Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions Jarogniew J. £uszczki1,2 Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, PL 20-090 Lublin, Poland Department of Physiopathology, Institute of Agricultural Medicine, Jaczewskiego 2, PL 20-950 Lublin, Poland Correspondence: Jarogniew J. £uszczki, e-mail: [email protected]; [email protected] Abstract: This review briefly summarizes the information on the molecular mechanisms of action, pharmacokinetic profiles and drug interac- tions of novel (third-generation) antiepileptic drugs, including brivaracetam, carabersat, carisbamate, DP-valproic acid, eslicar- bazepine, fluorofelbamate, fosphenytoin, ganaxolone, lacosamide, losigamone, pregabalin, remacemide, retigabine, rufinamide, safinamide, seletracetam, soretolide, stiripentol, talampanel, and valrocemide. These novel antiepileptic drugs undergo intensive clinical investigations to assess their efficacy and usefulness in the treatment of patients with refractory epilepsy. Key words: antiepileptic drugs, brivaracetam, carabersat, carisbamate, DP-valproic acid, drug interactions, eslicarbazepine, fluorofelbamate, fosphenytoin, ganaxolone, lacosamide, losigamone, pharmacokinetics, pregabalin, remacemide, retigabine, rufinamide, safinamide, seletracetam, soretolide, stiripentol, talampanel, valrocemide Abbreviations: 4-AP
    [Show full text]
  • Pharmaceutical Composition Comprising Brivaracetam and Lacosamide with Synergistic Anticonvulsant Effect
    (19) TZZ __T (11) EP 2 992 891 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.03.2016 Bulletin 2016/10 A61K 38/04 (2006.01) A61K 31/4015 (2006.01) A61P 25/08 (2006.01) (21) Application number: 15156237.8 (22) Date of filing: 15.06.2007 (84) Designated Contracting States: (71) Applicant: UCB Pharma GmbH AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 40789 Monheim (DE) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (72) Inventor: STOEHR, Thomas 2400 Mol (BE) (30) Priority: 15.06.2006 US 813967 P 12.10.2006 EP 06021470 (74) Representative: Dressen, Frank 12.10.2006 EP 06021469 UCB Pharma GmbH 22.11.2006 EP 06024241 Alfred-Nobel-Strasse 10 40789 Monheim (DE) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: Remarks: 07764676.8 / 2 037 965 This application was filed on 24-02-2015 as a divisional application to the application mentioned under INID code 62. (54) PHARMACEUTICALCOMPOSITION COMPRISING BRIVARACETAM AND LACOSAMIDE WITH SYNERGISTIC ANTICONVULSANT EFFECT (57) The present invention is directed to a pharmaceutical composition comprising (a) lacosamide and (b) brivara- cetam for the prevention, alleviation or/and treatment of epileptic seizures. EP 2 992 891 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 992 891 A1 Description [0001] The present application claims the priorities of US 60/813.967 of 15 June 2006, EP 06 021 470.7 of 12 October 2006, EP 06 021 469.9 of 12 October 2006, and EP 06 024 241.9 of 22 November 2006, which are included herein by 5 reference.
    [Show full text]
  • Can PDE Inhibition Improve Cognition? : Translational Insights
    Can PDE inhibition improve cognition? : Translational insights Citation for published version (APA): Reneerkens, O. A. H. (2013). Can PDE inhibition improve cognition? : Translational insights. Maastricht University. https://doi.org/10.26481/dis.20130418or Document status and date: Published: 01/01/2013 DOI: 10.26481/dis.20130418or Document Version: Publisher's PDF, also known as Version of record Please check the document version of this publication: • A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal. If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement: www.umlib.nl/taverne-license Take down policy If you believe that this document breaches copyright please contact us at: [email protected] providing details and we will investigate your claim.
    [Show full text]
  • Antiepileptic Potential of Ganaxolone Antiepileptički Potencijal Ganaksolona
    Vojnosanit Pregl 2017; 74(5): 467–475. VOJNOSANITETSKI PREGLED Page 467 UDC: 615.03::616.853-085 GENERAL REVIEW https://doi.org/10.2298/VSP151221157J Antiepileptic potential of ganaxolone Antiepileptički potencijal ganaksolona Slobodan Janković, Snežana Lukić Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia Key words: Ključne reči: ganaxolone; epilepsies, partial; neurotransmitter ganaksolon; epilepsije, parcijalne; neurotransmiteri; agents; child; adult. deca; odrasle osobe. Introduction New anticonvulsants With its estimated prevalence of 0.52% in Europe, The drug resistant epilepsy has been recently defined by 0.68% in the United States of America and up to 1.5% in de- the International League Against Epilepsy as “a failure of veloping countries, epilepsy makes a heavy burden on indi- adequate trials of two tolerated, appropriately chosen and viduals, healthcare systems and societies in general all over used antiepileptic drug schedules (whether as monotherapies the world 1, 2. Despite long history of epilepsy treatment with or in combination) to achieve sustained seizure free- dom” 11.The mechanisms of drug resistance in epilepsy are medication, efficacy and effectiveness of available antiepi- still incompletely understood, and none of the anticonvul- leptic drugs as monotherapy were unequivocally proven in sants with current marketing authorization has demonstrated clinical trials only for partial-onset seizures in children and superior efficacy in the treatment of drug resistant epilepsy 12. adults (including elderly), while generalized-onset tonic- Using new anticonvulsants as add-on therapy lead to free- clonic seizures in children and adults, juvenile myoclonic dom from seizures in only 6% of patients with drug resistant epilepsy and benign epilepsy with centrotemporal spikes are epilepsy 13.
    [Show full text]
  • Recent Molecular Enhancement Influenced by Natural Nootropic
    Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2016, Article ID 4391375, 12 pages http://dx.doi.org/10.1155/2016/4391375 Review Article Establishing Natural Nootropics: Recent Molecular Enhancement Influenced by Natural Nootropic Noor Azuin Suliman,1 Che Norma Mat Taib,1 Mohamad Aris Mohd Moklas,1 Mohd Ilham Adenan,2 Mohamad Taufik Hidayat Baharuldin,1 and Rusliza Basir1 1 DepartmentofHumanAnatomy,FacultyofMedicineandHealthSciences,UniversitiPutraMalaysia,43400Serdang,Malaysia 2Atta-ur-Rahman Institute for Natural Product Discovery, Aras 9 Bangunan FF3, UiTM Puncak Alam, Bandar Baru Puncak Alam, 42300 Selangor Darul Ehsan, Malaysia Correspondence should be addressed to Che Norma Mat Taib; [email protected] Received 31 May 2016; Accepted 18 July 2016 Academic Editor: Manel Santafe Copyright © 2016 Noor Azuin Suliman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Nootropics or smart drugs are well-known compounds or supplements that enhance the cognitive performance. They work by increasing the mental function such as memory, creativity, motivation, and attention. Recent researches were focused on establishing a new potential nootropic derived from synthetic and natural products. The influence of nootropic in the brain has been studied widely. The nootropic affects the brain performances through number of mechanisms or pathways, for example, dopaminergic pathway. Previous researches have reported the influence of nootropics on treating memory disorders, such as Alzheimer’s, Parkinson’s, and Huntington’s diseases. Those disorders are observed to impair the same pathways of the nootropics.
    [Show full text]
  • Telemetric EEG and the Rat: a Guide for Neuroscientists
    Editorial Telemetric EEG and the Rat: A Guide For Neuroscientists Jafri Malin AbdullAh1, Mohammad RAfiqul islAm2 1 Malaysian Journal of Medical Sciences, Universiti Sains Malaysia Press, Universiti Sains Malaysia Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia 2 Department of Neurosciences, School of Medical Sciences, Universiti Sains Malaysia Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia Abstract Telemetric EEG in the rat’s brain has been used for experiments which tests the effects of an antiepileptic compound on it’s antiseizures activity. A simple classification correlating epileptiform discharge and Racine’s behavioral activity is discussed. Keywords: electroencephalogram, neuroscience, rat, telemetry Animal models for seizures and epilepsy scale for the assessment of seizure intensities in have played a fundamental role in advancing our other epilepsy or seizure models is justifiable, understanding of basic mechanisms underlying given the well known relation between activated ictogenesis and epileptogenesis and have been brain part and corresponding expressed behavior instrumental in the discovery and preclinical of Sprague Dawley rats (160–350 g) which are development of novel antiepileptic drugs. suitable animals to induce status epilepticus Despite the successful development of various models and to record continuous EEG spikes and new antiepileptic drugs in recent decades, the wave discharges (4–6). search for new therapies with better efficacy and We used a total of 10 male Sprague Dawley tolerability remains an important goal (1). The and 6 Genetic Absence Epilepsy Rats from discovery and development of a new antiepileptic Strasbourg (GAERS) rats (7), four to six months drug relies heavily on the preclinical use of animal of age and weighing 187–325 g.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0021786 A1 Schenkel Et Al
    US 2011 0021786A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0021786 A1 Schenkel et al. (43) Pub. Date: Jan. 27, 2011 (54) PHARMACEUTICAL SOLUTIONS, PROCESS (86). PCT No.: PCT/EP09/524.54 OF PREPARATION AND THERAPEUTC USES S371 (c)(1), (2), (4) Date: Oct. 6, 2010 (75) Inventors: Eric Schenkel, Brussels (BE): Claire Poulain, Brussels (BE); (30) Foreign Application Priority Data Bertrand Dodelet, Brussels (BE): Domenico Fanara, Brussels (BE) Mar. 3, 2008 (EP) .................................. O8OO3915.9 Correspondence Address: Publication Classification MCDONNELL BOEHNEN HULBERT & BERG HOFF LLP (51) Int. Cl. 300 S. WACKER DRIVE, 32ND FLOOR C07D 207/27 (2006.01) CHICAGO, IL 60606 (US) (52) U.S. Cl. ........................................................ 548/SSO (73) Assignee: UCB PHARMA, S.A., Brussels (BE) (57) ABSTRACT (21) Appl. No.: 12/920,524 The present invention concerns a stable pharmaceutical solu tion, a process of the preparation thereof and therapeutic uses (22) PCT Filed: Mar. 2, 2009 thereof. US 2011/002 1786 A1 Jan. 27, 2011 PHARMACEUTICAL SOLUTIONS, PROCESS 0006 Seletracetam is effective in the treatment of epi OF PREPARATION AND THERAPEUTC lepsy. USES 0007. Until now, brivaracetam and seletracetam have been formulated in Solid compositions (film coated tablet, gran ules). 0008. However, an oral solution would be particularly desirable for administration in children and also in some adult 0001. The present invention concerns stable liquid formu patients. An injectable Solution could be advantageously used lations of 2-oxo-1-pyrrolodine derivatives, a process of the in case of epilepsy crisis. preparation thereof and therapeutic uses thereof. 0009 Moreover, administration of an oral dosage form is 0002 International patent application having publication the preferred route of administration for many pharmaceuti number WO 01/62726 discloses 2-oxo-1-pyrrolidine deriva cals because it provides for easy, low-cost administration.
    [Show full text]
  • Design and Study of Piracetam-Like Nootropics, Controversial Members of the Problematic Class of Cognition-Enhancing Drugs
    Current Pharmaceutical Design, 2002, 8, 125-138 125 Design and Study of Piracetam-like Nootropics, Controversial Members of the Problematic Class of Cognition-Enhancing Drugs Fulvio Gualtieri°*, Dina Manetti°, Maria Novella Romanelli° and Carla Ghelardini^ °Dipartimento di Scienze Farmaceutiche, Universita' di Firenze, Via G. Capponi 9, I-50121 Firenze, Italy ^Dipartimento di Farmacologia Preclinica e Clinica, Universita' di Firenze, Viale Pieraccini 6, I-50139 Firenze, Italy Abstract- Cognition enhancers are drugs able to facilitate attentional abilities and acquisition, storage and retrieval of information, and to attenuate the impairment of cognitive functions associated with head traumas, stroke, age and age-related pathologies. Development of cognition enhancers is still a difficult task because of complexity of the brain functions, poor predictivity of animal tests and lengthy and expensive clinical trials. After the early serendipitous discovery of first generation cognition enhancers, current research is based on a variety of working hypotheses, derived from the progress of knowledge in the neurobiopathology of cognitive processes. Among other classes of drugs, piracetam-like cognition enhancers (nootropics) have never reached general acceptance, in spite of their excellent tolerability and safety. In the present review, after a general discussion of the problems connected with the design and development of cognition enhancers, the class is examined in more detail. Reasons for the problems encountered by nootropics, compounds therapeutically available and those in development, their structure activity relationships and mechanisms of action are discussed. Recent developments which hopefully will lead to a revival of the class are reviewed. INTRODUCTION [3]. An extremely complicated neuronal network in the brain regulates the complex mechanism of learning and memory.
    [Show full text]
  • The Calcium/Calmodulin-Dependent Kinases II and IV As Therapeutic Targets in Neurodegenerative and Neuropsychiatric Disorders
    International Journal of Molecular Sciences Review The Calcium/Calmodulin-Dependent Kinases II and IV as Therapeutic Targets in Neurodegenerative and Neuropsychiatric Disorders Kinga Sałaciak 1, Aleksandra Koszałka 1, Elzbieta˙ Zmudzka˙ 2 and Karolina Pytka 1,* 1 Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland; [email protected] (K.S.); [email protected] (A.K.) 2 Department of Social Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland; [email protected] * Correspondence: [email protected] Abstract: CaMKII and CaMKIV are calcium/calmodulin-dependent kinases playing a rudimentary role in many regulatory processes in the organism. These kinases attract increasing interest due to their involvement primarily in memory and plasticity and various cellular functions. Although CaMKII and CaMKIV are mostly recognized as the important cogs in a memory machine, little is known about their effect on mood and role in neuropsychiatric diseases etiology. Here, we aimed to review the structure and functions of CaMKII and CaMKIV, as well as how these kinases modulate the animals’ behavior to promote antidepressant-like, anxiolytic-like, and procognitive effects. The review will help in the understanding of the roles of the above kinases in the selected neurodegenerative and neuropsychiatric disorders, and this knowledge can be used in future drug design. Citation: Sałaciak, K.; Koszałka, A.; Zmudzka,˙ E.; Pytka, K. The Keywords: CaMKII; CaMKIV; memory; depression; anxiety; animal studies Calcium/Calmodulin-Dependent Kinases II and IV as Therapeutic Targets in Neurodegenerative and Neuropsychiatric Disorders. Int. J. 1.
    [Show full text]
  • 9BT2018-MTI30.Pdf
    UNIDAD ACADÉMICA DE CIENCIAS DE LA SALUD Y BIENESTAR CARRERA DE MEDICINA TRABAJO DE GRADUACIÓN PREVIO A LA OBTENCIÓN DEL TÍTULO DE MÉDICO: “PREVALENCIA Y FACTORES ASOCIADOS AL CONSUMO DE MODAFINILO, DEXTROANFETAMINA Y METILFENIDATO EN ESTUDIANTES DE LAS FACULTADES DE MEDICINA DE LA CIUDAD DE CUENCA - 2018” AUTOR: MARIO FERNANDO FÁREZ BUENAÑO DIRECTOR: DRA. ROSA ELIZABETH SOLORZANO BERNITA ASESOR: LIC. CAREM FRANCELYS PRIETO FUENMAYOR CUENCA – ECUADOR 2018 Mario Fernando Fárez Buenaño 1 RESUMEN: Antecedentes: Desde 1960 se ha documentado el consumo de medicamentos psicoestimulantes, mismo que se ha incrementado últimamente. Por adolescentes y adultos jóvenes, especialmente estudiantes de nivel superior que utilizan estas sustancias con fines recreativos o para mejorar su desempeño académico. Objetivo: Determinar la prevalencia y factores asociados al consumo de Modafinilo, Metilfenidato y Dextroanfetamina en estudiantes de las Facultades de Medicina de las Universidades de la Ciudad de Cuenca - 2018. Materiales y Métodos: Estudio observacional analítico de cohorte transversal que abarcó 418 estudiantes de 18 – 25 años de las Facultades de Medicina de las Universidades de la ciudad de Cuenca -2018. Para el análisis se utilizó el programa IBM SPSS v. 24. La asociación estadística fue considerada con un índice de confiabilidad del 95%, con un valor estadístico de p<0.05. Resultados: La prevalencia del consumo corresponde al 3.88%, el fármaco más consumido es modafinilo 26.8%. Los factores asociados son: grupo étnico blanco OR: 3.64 (IC: 1.73-7.63, p: 0.00), o negro OR: 4.51 (IC: 1.14-17.73, p: 0.01), edad comprendida entre 22 – 25 años OR: 1.68 (IC: 1.10-2.57, p: 0.01), nivel socioeconómico alto OR:1.58 (IC: 1.01-2.49, p: 0.04), consumo de alcohol OR: 1.98 (IC: 1.00-3.90, p: 0.04), consumo de cannabis 4.54 (IC: 2.82-7.30, p: 0.00), tener amigos que consuman estos fármacos OR: 7.12 (IC: 4.34-11.68, p: 0.00).
    [Show full text]
  • Sunifiram | Medchemexpress
    Inhibitors Product Data Sheet Sunifiram • Agonists Cat. No.: HY-17550 CAS No.: 314728-85-3 Molecular Formula: C₁₄H₁₈N₂O₂ • Molecular Weight: 246.3 Screening Libraries Target: iGluR Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling Storage: 4°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) SOLVENT & SOLUBILITY In Vitro H2O : 50 mg/mL (203.00 mM; Need ultrasonic) DMSO : ≥ 2.6 mg/mL (10.56 mM) * "≥" means soluble, but saturation unknown. Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 4.0601 mL 20.3004 mL 40.6009 mL Stock Solutions 5 mM 0.8120 mL 4.0601 mL 8.1202 mL 10 mM 0.4060 mL 2.0300 mL 4.0601 mL Please refer to the solubility information to select the appropriate solvent. BIOLOGICAL ACTIVITY Description Sunifiram (DM-235) is a piperazine derived ampakine-like drug which has nootropic effects in animal studies with significantly higher potency than piracetam.IC50 value: Target: in vitro: DM 232 and DM 235 are novel antiamnesic compounds structurally related to ampakines. The involvement of AMPA receptors in the mechanism of action of DM 232 and DM 235 was, therefore, investigated in vivo and in vitro. Both compounds (0.1 mg/kg i.p.) were able to reverse the amnesia induced by the AMPA receptor antagonist NBQX (30 mg/kg i.p.) in the mouse passive avoidance test. At the effective doses, the investigated compounds did not impair motor coordination, as revealed by the rota rod test, nor modify spontaneous motility and inspection activity, as revealed by the hole board test [1].
    [Show full text]